Back to Results

Cytodyn Inc (CYDY)

CytoDyn Inc. is a clinical-stage biotechnology company listed on OTC Markets as common stock under the ticker CYDY. The company focuses on developing leronlimab, a humanized monoclonal antibody that targets the CCR5 receptor, for a range of therapeutic uses. Its development programs have included work in COVID-19 and oncology, with leronlimab currently in phase 2 studies for microsatellite stable colorectal cancer and certain solid tumors, including metastatic triple-negative breast cancer. CytoDyn also has a collaboration with Creatv Bio. The company was formerly known as RexRay Corporation and was incorporated in 2002. It is based in Vancouver, Washington.


Stock Summary Fair Value Profitability & Growth Quality & Risk Events & Dividends Market Outlook FAQ

Jump directly to the stock analysis sections supported by the latest available data.

Data update note: Fair value and stock analysis metrics are updated after regular market sessions when new data becomes available.
Ticker Fair Value Fair Value Upside/Downside Fair Value Rating Analyst Price Target Analyst Target Upside/Downside Overall Financial Health Dividend Yield Next Earnings Date Market Cap Enterprise Value Total Debt / Total Capital Free Float / Shares Outstanding Altman Z-Score Free Cash Flow / Net Income
OTC-CYDY
$0.20
-0.8% Downside
Fair
Not available
Not available
Fair
0.0%
October 28, 2026
295.1 M
327.9 M
8.0%
100.0%
-100.6
39.0%
Valuation • Fair Value

Cytodyn Inc (OTC-CYDY) Fair Value by Valuation Model

Review the available estimates for Cytodyn Inc (OTC-CYDY), including Comps Fair Value.

Primary Valuation Read

Fair Value

$0.20

Estimated downside of 0.8% versus the current market price.

Fair Value Confidence

Low

Confidence level for the primary fair value estimate.

Comps Fair Value

$0.20

Comparable-company valuation reference.

Analyst Price Target

Not available

Data is currently unavailable.

How to read these valuation models

Use the 3 available valuation references for Cytodyn Inc (OTC-CYDY) as analytical inputs, not a standalone conclusion. Valuation methods can differ because they rely on different assumptions, time horizons and financial inputs; compare the estimates with the current price and the company’s financial quality.

Profitability • Growth

Profitability & Growth for Cytodyn Inc (OTC-CYDY)

Review the profitability and growth indicators currently supported by the latest data.

Revenue Forecast

0 K

Forward revenue estimate.

EBITDA

-23.128 M

Current operating profitability reference.

How to read profitability and growth

This section helps investors review Cytodyn Inc (OTC-CYDY) from an operating perspective by combining current scale, forward revenue expectations and EBITDA-related profitability measures.

Quality • Risk

Quality & Financial Risk for Cytodyn Inc (OTC-CYDY)

Review the financial quality and risk indicators currently supported by the latest data.

Financial Health

Fair

Mixed or neutral financial-health read.

Piotroski Score

1

Weak quality score that deserves closer review.

Altman Z-Score

-100.6

Lower score that deserves closer risk review.

FCF / Net Income

39.0%

Cash conversion quality indicator.

How to read quality and risk

This section combines quality, balance-sheet and accounting-risk indicators for Cytodyn Inc (OTC-CYDY). Read the metrics together: no single score is a complete investment conclusion, but the combined view can highlight financial strength, earnings quality and areas that may deserve closer review.

Events • Dividends

Upcoming Events & Dividends for Cytodyn Inc (OTC-CYDY)

Track the upcoming dates and dividend metrics currently supported by the latest data.

Next Earnings Date

October 28, 2026

Days to Earnings

36

Dividend Yield

0.0%

No current dividend yield is indicated.

How to read events and dividends

This section helps investors track time-sensitive items for Cytodyn Inc (OTC-CYDY), including the next earnings date and dividend-related milestones. These items can matter for short-term volatility, income planning and event-driven positioning.

Stock Forecast • Technical Outlook

Cytodyn Inc (OTC-CYDY) Stock Forecast & Technical Outlook

Review Cytodyn Inc (OTC-CYDY) across multiple technical time frames, alongside analyst recommendation data, to form a faster read on market positioning and near-term sentiment.

Technical Signals by Time Frame

Switch between time frames to review the current technical signal for the stock.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 15-minute • intraday
Strong Sell

The 15-minute technical read for Cytodyn Inc (OTC-CYDY) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 1-hour • short-term
Strong Sell

The 1-hour technical read for Cytodyn Inc (OTC-CYDY) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: daily • daily
Neutral

The daily technical read for Cytodyn Inc (OTC-CYDY) is currently Neutral. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: weekly • weekly
Strong Sell

The weekly technical read for Cytodyn Inc (OTC-CYDY) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: monthly • monthly
Strong Sell

The monthly technical read for Cytodyn Inc (OTC-CYDY) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Analyst Consensus for Cytodyn Inc (OTC-CYDY)

A consolidated view of buy, hold and sell recommendations based on the currently available analyst data.

Strong Sell Sell Neutral Buy Strong Buy
Consolidated analyst recommendation mix
Hold

Based on the available recommendation mix, Cytodyn Inc (OTC-CYDY) has a Hold consensus, with 0 buy, 1 hold and 0 sell recommendations in the current data set.

Buy 0
Hold 1
Sell 0
FAQ • Fast Investor Answers

Cytodyn Inc (OTC-CYDY) Stock FAQ

Data-supported answers about Cytodyn Inc (OTC-CYDY), including explicit coverage status where a reliable valuation estimate is not currently available.

Fair Value
$0.20
Estimated downside 0.8%
Valuation Rating
Near Fair Value
Price is close to fair value
Financial Health
Fair
Current financial-health read

The current fair value estimate for Cytodyn Inc (OTC-CYDY) is $0.20. This implies an estimated downside of 0.8% versus the current market price.

Based on the current fair value estimate, the stock is trading close to its estimated fair value.

The current financial health read for Cytodyn Inc (OTC-CYDY) is Fair. This should be reviewed alongside valuation, profitability, debt and cash-flow quality metrics.

The next earnings date currently listed for Cytodyn Inc (OTC-CYDY) is October 28, 2026.

The latest available data indicates no current dividend yield for Cytodyn Inc (OTC-CYDY).

The current market capitalization listed for Cytodyn Inc is 295.1 M.

The current enterprise value listed for Cytodyn Inc is 327.9 M. Enterprise value can provide a broader valuation view than market capitalization alone because it also considers net debt.

The ticker symbol for Cytodyn Inc is OTC-CYDY, and the stock is listed on OTC Markets.

Cytodyn Inc (OTC-CYDY) is listed on OTC Markets.

The current debt-to-total-capital ratio listed for Cytodyn Inc is 8.0%, which helps investors evaluate the company’s financing structure and leverage profile.

The free float listed for Cytodyn Inc is 100.0%. Free float helps investors understand how much of the share base is available for public trading.

Similar Biotechnology Stocks View more on OTC Markets

Comparable companies from the same industry, limited to one security per issuer.

ABBV NYSE AbbVie Inc Fair Value Fair Market Cap 468.7 B
AMGN NASDAQ Amgen Inc Fair Value Fair Market Cap 221.8 B
GILD NASDAQ Gilead Sciences Inc Fair Value Fair Market Cap 189.3 B
VRTX NASDAQ Vertex Pharmaceuticals Inc Fair Value Fair Market Cap 130.5 B
REGN NASDAQ Regeneron Pharmaceuticals Inc Fair Value Undervalued Market Cap 80.273 B
MRNA NASDAQ Moderna Inc Fair Value Overvalued Market Cap 72.885 B
ARGX NASDAQ argenx NV ADR Fair Value Fair Market Cap 61.249 B
NTRA NASDAQ Natera Inc Fair Value Overvalued Market Cap 56.346 B
ONC NASDAQ BeOne Medicines AG DRC Fair Value Fair Market Cap 41.851 B
RVMD NASDAQ Revolution Medicines Inc Fair Value Fair Market Cap 41.337 B
ALNY NASDAQ Alnylam Pharmaceuticals Inc Fair Value Fair Market Cap 33.673 B
BIIB NASDAQ Biogen Inc Fair Value Fair Market Cap 33.298 B
ROIV NASDAQ Roivant Sciences Ltd Fair Value Overvalued Market Cap 27.607 B
INSM NASDAQ Insmed Inc Fair Value Fair Market Cap 26.385 B
INCY NASDAQ Incyte Corporation Fair Value Fair Market Cap 25.728 B
BNTX NASDAQ BioNTech SE Fair Value Fair Market Cap 25.339 B
UTHR NASDAQ United Therapeutics Corporation Fair Value Fair Market Cap 21.342 B
GMAB NASDAQ Genmab AS Fair Value Overvalued Market Cap 20.853 B
ASND NASDAQ Ascendis Pharma AS Fair Value Fair Market Cap 15.602 B
NBIX NASDAQ Neurocrine Biosciences Inc Fair Value Undervalued Market Cap 14.46 B